A new study that used the phage PASA16 to treat difficult Pseudomonas aeruginosa infections yielded encouraging results, with an 86.6% success rate. With 16 individuals suffering from recurrent infections, this is the largest study of its sort. Phage treatment was used in conjunction with antibiotics and was shown to be efficacious in 13 of 15 patients with sufficient data. Treatment times vary from 8 days to 6 weeks, making it a convenient alternative. The study shows that phage PASA16 has the potential to be used as an alternative treatment for difficult-to-treat Pseudomonas aeruginosa infections, which are widespread in hospitals. In immunocompromised people, Pseudomonas aeruginosa can cause serious infections. While phage treatment offers promise, clinical trials are still in their early stages.

To know more: About the original article click here.